| Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer (NCT05284552) | University Hospital, Linkoeping | 2022-07-12 |
| A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) (NCT05429970) | Memorial Sloan Kettering Cancer Center | 2022-06-17 |
| A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi (NCT05385068) | Peking Union Medical College Hospital | 2022-06-01 |
| [18F]Fluoro-PEG-folate PET/CT Imaging in Epithelial Ovarian Cancer (NCT05215496) | Lioe-Fee de Geus-Oei, MD PhD | 2022-05-10 |
| WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC (NCT04644289) | AGO Research GmbH | 2022-05-05 |
| A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors (NCT05293496) | MacroGenics | 2022-04-19 |
| CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER) (NCT05316181) | National Cancer Center, Korea | 2022-04-07 |
| HRD and Resistance to PAPPi in EOC Patients (NCT05310370) | Lei Li | 2022-03-26 |
| Chromosomal Instability in Ovarian Cancer (NCT05310357) | Lei Li | 2022-03-26 |
| Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer (NCT05236686) | Shanghai Gynecologic Oncology Group | 2022-02-15 |
| Vitamin D and Pre Cachexia and Cancer Cachexia in Epithelial Ovarian Cancer (NCT04864431) | Indonesia University | 2022-01-12 |
| PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer (NCT05187208) | Seoul National University Hospital | 2022-01-01 |
| A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies (NCT05199272) | 23andMe, Inc. | 2021-12-29 |
| Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC (NCT04983550) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-09-01 |
| Individualized Health Management of Epithelial Ovarian Cancer: A Retrospective Study (NCT06085456) | RenJi Hospital | 2021-09-01 |
| Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (NCT04986371) | Ling-Ying Wu | 2021-08-10 |
| A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer (NCT04846842) | Lee's Pharmaceutical Limited | 2021-07-01 |
| Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy (NCT03607955) | Washington University School of Medicine | 2021-06-30 |
| Study of XB002 in Subjects With Solid Tumors (JEWEL-101) (NCT04925284) | Exelixis | 2021-06-07 |
| PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI (NCT05172310) | Karolinska University Hospital | 2021-06-02 |
| Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors (NCT04902872) | Cybrexa Therapeutics | 2021-05-03 |
| CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (NCT04676334) | pharmaand GmbH | 2021-03-22 |
| TH1902 in Patients With Advanced Solid Tumors (NCT04706962) | Theratechnologies | 2021-03-04 |
| The INFLUENCE of Cytoreduction on PRO in EOC (NCT03268876) | Haukeland University Hospital | 2021-03-03 |
| Rectosigmoid Resection vs Seromuscular Tumor Shaving in Ovarian Cancer Surgery (NCT04665635) | Cukurova University | 2021-03-01 |
| Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) (NCT04726332) | Exelixis | 2021-02-10 |
| Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian (NCT04670068) | UNC Lineberger Comprehensive Cancer Center | 2021-01-27 |
| Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS) (NCT04515602) | Shanghai Gynecologic Oncology Group | 2021-01-01 |
| A Training Set for the HRD Model in EOC (NCT04651933) | Lei Li | 2020-11-26 |
| A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer (NCT04651920) | Lei Li | 2020-11-26 |
| Cell-free DNA Methylation for Epithelial Ovarian Cancer (NCT04651946) | Lei Li | 2020-11-26 |
| A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer (NCT04562298) | Shanghai East Hospital | 2020-10-21 |
| Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (NCT04620954) | National Cancer Centre, Singapore | 2020-10-07 |
| Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer (NCT04546373) | Grupo Español de Investigación en Cáncer de Ovario | 2020-09-30 |
| Determining Prognostic Immune Markers in Patients With Ovarian Cancer (NCT03862677) | Leiden University Medical Center | 2020-08-15 |
| PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer (NCT04493619) | Opna Bio LLC | 2020-08-11 |
| 68Ga-FAPI-04 and 18F-FDG PET/CT in Patients With Epithelial Ovarian Cancer: Compared With Histological Findings (NCT04504110) | Peking Union Medical College Hospital | 2020-08-05 |
| A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation (NCT04473339) | CAI Hongbing | 2020-08-01 |
| Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study (NCT04539327) | Grupo Español de Investigación en Cáncer de Ovario | 2020-07-29 |
| A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (NCT04296890) | ImmunoGen, Inc. | 2020-07-23 |
| Efficacy of Letrozole in Recurrent Ovarian Cancer (NCT04421547) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2020-06-22 |
| Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors (NCT04429542) | Bicara Therapeutics | 2020-06-01 |
| Translational Analysis In Longitudinal Series of Ovarian Cancer ORganoids (NCT04555473) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2020-05-12 |
| Platino-resistance in Ovarian Cancer (NCT03954171) | Institut Claudius Regaud | 2020-03-06 |
| Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) (NCT04152499) | Klus Pharma Inc. | 2020-02-28 |
| A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression (NCT04209855) | AbbVie | 2019-12-31 |
| Genetic Mutation in Epithelial Ovarian Cancer (NCT04191252) | Lei Li | 2019-12-19 |
| Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer (NCT04190667) | Lei Li | 2019-12-07 |
| Genomic BRCA and Extensive ovArian Cancer Testing (NCT04027868) | ARCAGY/ GINECO GROUP | 2019-12-06 |
| The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer (NCT06086665) | Asan Medical Center | 2019-12-01 |
| Development of a Biomarker to Predict the Efficacy of Anti-angiogenic Therapy in Ovarian Cancer (NCT05874115) | Centro di Riferimento Oncologico - Aviano | 2019-10-17 |
| Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery (NCT03373058) | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 2019-10-15 |
| Diagnosis of Epithelial Ovarian Cancer Using Ovarian Cancer Score (OCS) Test (NCT06366997) | Chongqing University Cancer Hospital | 2019-10-09 |
| Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer (NCT04101760) | Lei Li | 2019-10-01 |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) (NCT03824704) | pharmaand GmbH | 2019-08-23 |
| Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients (NCT03933813) | University of Wisconsin, Madison | 2019-07-29 |
| A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (NCT03849469) | Xencor, Inc. | 2019-05-29 |
| Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE) (NCT04279509) | National University Hospital, Singapore | 2019-05-29 |
| A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (NCT03872947) | Toray Industries, Inc | 2019-04-26 |
| Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer (NCT03692637) | Allife Medical Science and Technology Co., Ltd. | 2019-03-01 |
| Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse (NCT04015739) | ARCAGY/ GINECO GROUP | 2019-03-01 |
| Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer (NCT03622385) | Baylor Research Institute | 2019-02-19 |
| Long-acting G-CSF for Febrile Neutropenia (NCT03740464) | Lei Li | 2018-11-10 |
| A Multi-omics Study of Epithelial Ovarian Cancer (NCT03742856) | Lei Li | 2018-11-10 |
| Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) (NCT03393884) | Imunon | 2018-09-05 |
| Microscopic Peritoneal Metastases After Complete Macroscopic Cytoreductive Surgery for Epithelial Ovarian Cancer (NCT03754569) | Assistance Publique - Hôpitaux de Paris | 2018-06-01 |
| Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer (NCT03180177) | Shu-Zhong Cui | 2018-03-01 |
| Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients (NCT03321188) | Andrea Jewell | 2017-12-15 |
| Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int (NCT03213964) | Masonic Cancer Center, University of Minnesota | 2017-10-19 |
| Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer (NCT03371693) | Zhongnan Hospital | 2017-09-30 |
| Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer. (NCT03155451) | RenJi Hospital | 2017-08-14 |
| A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. (NCT03106987) | AstraZeneca | 2017-06-08 |
| Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab (NCT03093155) | Yale University | 2017-04-03 |
| Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia (NCT04001023) | Turku University Hospital | 2017-03-09 |
| Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (NCT03100006) | National Cancer Centre, Singapore | 2017-02-22 |
| Ovarian Tumor Biopsies to Study Response to Treatments (NCT02952521) | University Health Network, Toronto | 2017-01-25 |
| Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). (NCT02834975) | University of Miami | 2016-12-22 |
| Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer (NCT02900560) | Translational Research in Oncology | 2016-12-20 |
| Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer (NCT02915523) | Syndax Pharmaceuticals | 2016-12-19 |
| HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma (NCT02947152) | Novartis Pharmaceuticals | 2016-12-01 |
| Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer (NCT02943317) | Verastem, Inc. | 2016-10-01 |
| HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma (NCT02487849) | Krankenhaus Barmherzige Schwestern Linz | 2016-08-01 |
| Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) (NCT02859038) | Shanghai Gynecologic Oncology Group | 2016-08-01 |
| A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers (NCT02728830) | AA Secord | 2016-06-01 |
| Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (NCT02644369) | University Health Network, Toronto | 2016-03-21 |
| Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer (NCT02606305) | ImmunoGen, Inc. | 2016-03-02 |
| A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (NCT02631876) | ImmunoGen, Inc. | 2016-03-02 |
| LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer (NCT02668913) | Geoff Hall | 2016-02-01 |
| A Study of Long-Term Responders on Olaparib (NCT02489058) | University Health Network, Toronto | 2016-02-01 |
| Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer (NCT02480374) | Imunon | 2015-09-01 |
| Total/Subtotal Colectomy in Ovarian Cancer (NCT02595021) | Shanghai Gynecologic Oncology Group | 2015-07-01 |
| Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation (NCT02477202) | Memorial Sloan Kettering Cancer Center | 2015-06-01 |
| Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission (NCT02324439) | Southern Illinois University | 2015-03-01 |
| Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs. (NCT02323568) | Centre Francois Baclesse | 2014-12-01 |
| GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer (NCT02012192) | Medical University Innsbruck | 2014-07-04 |
| HOT: HIPEC in Ovarian Cancer as Initial Treatment (NCT02124421) | Mercy Medical Center | 2014-04-01 |
| Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer (NCT02022917) | Chang Gung Memorial Hospital | 2014-03-01 |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) (NCT01891344) | pharmaand GmbH | 2013-10-30 |
| Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer (NCT03332576) | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 2013-08-23 |
| Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy (NCT02728492) | NewVac LLC | 2013-08-01 |